RU2015149114A - Стабилизированная композиция пеметрекседа - Google Patents
Стабилизированная композиция пеметрекседа Download PDFInfo
- Publication number
- RU2015149114A RU2015149114A RU2015149114A RU2015149114A RU2015149114A RU 2015149114 A RU2015149114 A RU 2015149114A RU 2015149114 A RU2015149114 A RU 2015149114A RU 2015149114 A RU2015149114 A RU 2015149114A RU 2015149114 A RU2015149114 A RU 2015149114A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- pemetrexed
- cysteine
- acetyl
- pharmaceutically acceptable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 24
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 title claims 20
- 229960005079 pemetrexed Drugs 0.000 title claims 20
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 6
- 239000001509 sodium citrate Substances 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000011261 inert gas Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 229910001873 dinitrogen Inorganic materials 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Claims (13)
1. Композиция пеметрекседа, содержащая пеметрексед или его фармацевтически приемлемую соль в качестве активного ингредиента, N-ацетил-L-цистеин и цитрат натрия.
2. Композиция пеметрекседа по п. 1, в которой отношение концентраций пеметрекседа или его фармацевтически приемлемой соли, N-ацетил-L-цистеина и цитрата натрия составляет 1-30:0,15-2,0:1,0-15,0.
3. Композиция пеметрекседа по п. 2, в которой отношение концентраций пеметрекседа или его фармацевтически приемлемой соли, N-ацетил-L-цистеина и цитрата натрия составляет 1-30:1,5:1,0-15,0.
4. Композиция пеметрекседа по п. 1, где данная композиция представляет собой жидкую композицию, которую можно хранить в состоянии раствора.
5. Композиция пеметрекседа по п. 1, где данная композиция представляет собой жидкую композицию для инъекции в герметичном готовом к употреблению контейнере.
6. Композиция пеметрекседа в герметичном контейнере, содержащая пеметрексед или его фармацевтически приемлемую соль в качестве активного ингредиента, где данная композиция имеет в свободном пространстве контейнера содержание газообразного кислорода 3% об./об. или менее относительно общего объема свободного пространства.
7. Композиция пеметрекседа по п. 6, где данная композиция дополнительно содержит N-ацетил-L-цистеин и цитрат натрия.
8. Композиция пеметрекседа по п. 7, в которой отношение концентраций пеметрекседа или его фармацевтически приемлемой соли, N-ацетил-L-цистеина и цитрата натрия составляет 1-30: 0,15-2,0: 1,0-15,0.
9. Композиция пеметрекседа по п. 8, в которой отношение концентраций пеметрекседа или его фармацевтически приемлемой соли, N-ацетил-L-цистеина и цитрата натрия составляет 1-30:1,5:1,0-15,0.
10. Композиция пеметрекседа по п. 6, где данная композиция представляет собой жидкую композицию, которую можно хранить в состоянии раствора.
11. Композиция пеметрекседа по п. 6, где данная композиция представляет собой жидкую композицию для инъекции в герметичном готовом к употреблению контейнере.
12. Композиция пеметрекседа по п. 6, в которой содержание газообразного кислорода корректируют заменой газообразного кислорода в свободном пространстве контейнера инертным газом.
13. Композиция пеметрекседа по п. 12, в которой инертный газ представляет собой газообразный азот или газообразный аргон.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130052083A KR101485243B1 (ko) | 2013-05-08 | 2013-05-08 | 안정화된 페메트렉시드 제제 |
| KR10-2013-0052083 | 2013-05-08 | ||
| PCT/KR2014/004105 WO2014182093A1 (ko) | 2013-05-08 | 2014-05-08 | 안정화된 페메트렉시드 제제 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015149114A true RU2015149114A (ru) | 2017-06-09 |
| RU2636783C2 RU2636783C2 (ru) | 2017-11-28 |
Family
ID=51867494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015149114A RU2636783C2 (ru) | 2013-05-08 | 2014-05-08 | Стабилизированная композиция пеметрекседа |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9629844B2 (ru) |
| EP (1) | EP2995298B1 (ru) |
| JP (1) | JP6159879B2 (ru) |
| KR (1) | KR101485243B1 (ru) |
| CN (1) | CN105451717B (ru) |
| BR (1) | BR112015028124B1 (ru) |
| CL (1) | CL2015003266A1 (ru) |
| ES (1) | ES2890523T3 (ru) |
| HK (1) | HK1218076A1 (ru) |
| MX (1) | MX362807B (ru) |
| PH (1) | PH12015502542A1 (ru) |
| RU (1) | RU2636783C2 (ru) |
| WO (1) | WO2014182093A1 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101260636B1 (ko) * | 2012-11-29 | 2013-05-13 | 씨제이제일제당 (주) | 안정화된 페메트렉시드 제제 |
| CN110051625A (zh) | 2013-10-03 | 2019-07-26 | 富士胶片株式会社 | 注射液制剂及其制造方法 |
| JP6120766B2 (ja) * | 2013-12-27 | 2017-04-26 | 富士フイルム株式会社 | 注射液製剤及びその製造方法 |
| KR101770605B1 (ko) * | 2014-11-17 | 2017-08-23 | 동아에스티 주식회사 | 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물 |
| WO2016082714A1 (zh) * | 2014-11-26 | 2016-06-02 | 台湾东洋药品工业股份有限公司 | 具有长期稳定性的不含抗氧化剂的药物注射溶液的制备方法 |
| JP6869899B2 (ja) | 2015-02-13 | 2021-05-12 | サン・ファーマシューティカル・インダストリーズ・リミテッド | 静脈内注入剤形 |
| KR101919436B1 (ko) | 2015-05-28 | 2018-11-16 | 주식회사 삼양바이오팜 | 안정화된 약학 조성물 및 그의 제조방법 |
| KR101693675B1 (ko) | 2015-12-14 | 2017-01-06 | 주식회사 종근당 | 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물 |
| JP6837895B2 (ja) * | 2017-04-04 | 2021-03-03 | 日本化薬株式会社 | 医薬品溶液製剤の製造方法 |
| US10369077B2 (en) * | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
| EP3675819A1 (en) * | 2017-08-29 | 2020-07-08 | Fresenius Kabi Oncology Limited | Stable liquid compositions of pemetrexed |
| EA202191345A1 (ru) * | 2018-11-14 | 2021-10-08 | Авм Байотекнолоджи, Ллс | Стабильный состав глюкокортикоидов |
| WO2021192471A1 (ja) * | 2020-03-24 | 2021-09-30 | ナガセ医薬品株式会社 | ペメトレキセド製剤 |
| WO2023237093A1 (zh) * | 2022-06-09 | 2023-12-14 | 上海云晟研新生物科技有限公司 | 培美曲塞二钠液体组合物、其制备方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| CA2032695A1 (en) | 1989-12-20 | 1991-06-21 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
| EA004708B1 (ru) | 2000-02-04 | 2004-06-24 | Эли Лилли Энд Компани | Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой |
| US6686365B2 (en) | 2000-02-04 | 2004-02-03 | Eli Lilly And Company | Pharmaceutical composition |
| EP1259513B1 (en) * | 2000-02-25 | 2003-09-10 | Eli Lilly And Company | A NOVEL CRYSTALLINE FORM OF N- 4- 2-(2-AMINO-4,7-DIHYDRO-4-OXO-3H-PYRROLO 2,3-d]PYRIMIDIN-5-YL)ETHYL]BENZOYL]-L-GLUTAMIC ACID AND PROCESS THEREFOR |
| KR100774366B1 (ko) | 2001-09-10 | 2007-11-08 | 주식회사 중외제약 | 파클리탁셀 주사제 조성물 |
| JP2007528384A (ja) | 2004-03-10 | 2007-10-11 | シモダ、バイオテック（プロプライエタリー）リミテッド | 安定な注射可能なジクロフェナク組成物 |
| EP2072518A1 (en) * | 2007-12-23 | 2009-06-24 | Sun Pharma Advanced Research Company Limited | Stable Amorphous Form of Pemextred Disodium |
| WO2010030598A2 (en) * | 2008-09-11 | 2010-03-18 | Dr. Reddy's Laboratories Limited | Pharmaceutical formulations comprising pemetrexed |
| CA2804855A1 (en) * | 2010-07-28 | 2012-02-02 | Eagle Pharmaceuticals, Inc. | Pharmaceutical compositions containing pemetrexed having extended storage stability |
| KR101069128B1 (ko) | 2011-03-10 | 2011-09-30 | 건일제약 주식회사 | 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법 |
| EP2854768B1 (en) * | 2012-05-30 | 2017-03-22 | Fresenius Kabi Oncology Limited | Pharmaceutical compositions of pemetrexed |
| KR101260636B1 (ko) * | 2012-11-29 | 2013-05-13 | 씨제이제일제당 (주) | 안정화된 페메트렉시드 제제 |
-
2013
- 2013-05-08 KR KR20130052083A patent/KR101485243B1/ko active IP Right Grant
-
2014
- 2014-05-08 RU RU2015149114A patent/RU2636783C2/ru active
- 2014-05-08 US US14/889,749 patent/US9629844B2/en active Active
- 2014-05-08 CN CN201480025982.8A patent/CN105451717B/zh active Active
- 2014-05-08 ES ES14795085T patent/ES2890523T3/es active Active
- 2014-05-08 BR BR112015028124-9A patent/BR112015028124B1/pt active IP Right Grant
- 2014-05-08 MX MX2015015356A patent/MX362807B/es active IP Right Grant
- 2014-05-08 JP JP2016512837A patent/JP6159879B2/ja active Active
- 2014-05-08 EP EP14795085.1A patent/EP2995298B1/en active Active
- 2014-05-08 WO PCT/KR2014/004105 patent/WO2014182093A1/ko active Application Filing
-
2015
- 2015-11-06 CL CL2015003266A patent/CL2015003266A1/es unknown
- 2015-11-06 PH PH12015502542A patent/PH12015502542A1/en unknown
-
2016
- 2016-05-31 HK HK16106166.7A patent/HK1218076A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101485243B1 (ko) | 2015-01-21 |
| EP2995298A4 (en) | 2017-01-25 |
| US9629844B2 (en) | 2017-04-25 |
| CN105451717A (zh) | 2016-03-30 |
| RU2636783C2 (ru) | 2017-11-28 |
| US20160120867A1 (en) | 2016-05-05 |
| PH12015502542B1 (en) | 2016-02-22 |
| JP6159879B2 (ja) | 2017-07-05 |
| ES2890523T3 (es) | 2022-01-20 |
| BR112015028124B1 (pt) | 2023-02-28 |
| EP2995298B1 (en) | 2021-06-23 |
| CN105451717B (zh) | 2018-05-22 |
| BR112015028124A2 (pt) | 2017-07-25 |
| PH12015502542A1 (en) | 2016-02-22 |
| EP2995298A1 (en) | 2016-03-16 |
| MX2015015356A (es) | 2016-03-04 |
| KR20140132621A (ko) | 2014-11-18 |
| JP2016518404A (ja) | 2016-06-23 |
| WO2014182093A1 (ko) | 2014-11-13 |
| HK1218076A1 (zh) | 2017-02-03 |
| MX362807B (es) | 2019-02-13 |
| CL2015003266A1 (es) | 2016-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015149114A (ru) | Стабилизированная композиция пеметрекседа | |
| RU2015122023A (ru) | Стабилизированная композиция пеметрекседа | |
| SG2013049325A (en) | High concentration antibody- containing liquid formulation | |
| TN2014000431A1 (en) | Antibody formulatoin | |
| WO2012094244A3 (en) | Container with an absorbent support below the filter | |
| MY188598A (en) | Dexmedetomidine premix formulation | |
| WO2011123298A3 (en) | Oxygen and carbon dioxide absorption in a single use container | |
| RU2014147365A (ru) | Инъецируемые составы апрепитанта | |
| WO2012035480A3 (en) | Pharmaceutical compositions of curcumin | |
| JP2017514924A5 (ru) | ||
| ZA201504103B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
| HRP20220626T1 (hr) | Otopine bimatoprosta i timolola bez konzervansa | |
| RU2012100622A (ru) | Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении рака | |
| RU2014147388A (ru) | Лекарственная форма гемцитабина большого объема для инфузии и комплект, включающий лекарственную форму | |
| HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
| PH12016500909B1 (en) | Solutons for increasing the stability and shelf life of an organ tissue preservation solution | |
| EA201401309A1 (ru) | Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение | |
| JP2015224251A5 (ru) | ||
| NZ710193A (en) | Agent for elevating nitric oxide concentration | |
| ES2895690T1 (es) | Método para producir una solución de éster de bortezomib | |
| WO2012124948A3 (ko) | 질소 냉장고에 사용되는 식품 저장용기 | |
| MX2013005306A (es) | Composicion farmaceutica. | |
| WO2012161520A3 (ko) | 도세탁셀을 함유하는 액상 주사용 조성물 | |
| PH12020500532A1 (en) | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin | |
| AR092799A1 (es) | Composiciones y metodos para inhibir la precipitacion de colorantes en una bebida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |